BELIEVE BIG
Face It. Fight It. Overcome It.™

Mistletoe Therapy – Frequently Asked Questions for Conventional Medical Providers

Purpose:
To provide clear, evidence-based answers to common questions from conventional oncology physicians regarding the safe and integrative use of mistletoe therapy in cancer care.

What is mistletoe?
Mistletoe (Viscum album) is a semiparasitic plant whose extracts have been studied for potential anticancer effects. Laboratory studies have shown that mistletoe extracts can:

- Kill cancer cells in vitro [1–10]
- Down-regulate tumor progression genes such as TGF-beta and matrix metalloproteinases [11,12]
- Enforce natural killer (NK) cell–mediated tumor cell lysis
- Reduce tumor cell migration and invasion
- Stimulate immune cells both in vitro and in vivo [10–31]
- Improved QOL measures across all studies (Quality of Life)

Three components — viscotoxins, polysaccharides, and lectins — are thought to be largely responsible for these effects. Viscotoxins are small proteins with cytotoxic and immune-stimulating potential, while lectins are protein–carbohydrate complexes that can bind immune cells and induce biochemical responses. Other synergistic compounds are likely present in Mistletoe still under study.

What is the proposed mechanism of action in cancer patients?
Primarily immune modulation (activation of NK cells, dendritic cells, and cytokine signaling), with tumor-microenvironment effects (e.g., anti-inflammatory signaling) and direct cytotoxicity from lectins/viscotoxins at certain doses. Preclinical work also suggests anti-angiogenic activity. Clinical use focuses on QOL and treatment tolerance; disease-modifying effects remain an area of study.

Is mistletoe therapy intended to replace conventional cancer treatment?
No. Mistletoe therapy is not a replacement for surgery, chemotherapy, immunotherapy, or radiation. It is used alongside standard treatments with the goal of improving quality of life, supporting immune function, and mitigating treatment-related side effects. There is no evidence that Mistletoe inhibits other anti-cancer applications.

What does the scientific evidence say?
Over 160 clinical studies and observational trials (particularly from Europe) suggest that mistletoe therapy may:

• Improve quality of life measures (energy, mood, appetite)
• Reduce chemotherapy-related fatigue and nausea
• Support immune modulation by stimulating NK cell activity and cytokine release
• Improve treatment tolerance and reduce hospitalization time

A **Phase 1 clinical trial** at The Johns Hopkins University School of Medicine, conducted in collaboration with Believe Big, was published in the Cancer Research journal. **Phase 2** is scheduled to begin this year.

How is it administered?
• Subcutaneous injection (most common): 2–3 times per week, escalate based on local reaction, temperature response, and patient-reported QOL.
• Intravenous infusion: Used in specific clinical contexts, under physician supervision.
Treatment is individualized, with dosing tailored to patient tolerance and clinical goals.

Setting for administration?
• **Clinic-administered** for initiation, education, and IV protocols.
• **Home self-injection** (SC) is common after training and first-dose observation, with periodic clinical follow-up.

Are there interactions with chemotherapy, immunotherapy, or radiation?
• **Chemotherapy:** No consistent evidence of **reduced cytotoxic efficacy**. Many centers co-administer during chemotherapy to support tolerance. As with any immunomodulator, monitor closely with **myelosuppressive** or **narrow-therapeutic-index** agents. Can be given concurrently; may reduce chemo-related side effects without reducing efficacy.
• **Immunotherapy:** Use with checkpoint inhibitors (e.g., pembrolizumab, nivolumab) has been documented without evidence of negative interaction, though close monitoring is advised. Case series and clinical experience suggest **concurrent use is feasible** without blunting ICI activity. Because both influence immune tone, monitor for **immune-related AEs** and adjust if exaggerated inflammatory responses occur.
• **Radiation:** May improve skin tolerance and reduce fatigue
Mistletoe's mechanism of action involves immune modulation rather than direct cytotoxic interference with conventional agents.

Any pharmacokinetic interactions?
No well-documented clinically significant PK interactions (CYP/P-gp) have been established.

What are the safety considerations?
• Generally well-tolerated
• Common, mild effects: Local redness/swelling at injection site, mild fever, or flu-like symptoms — often interpreted as an immune response
• Rare: Allergic reaction or hypersensitivity
• **Contraindications:** Avoid in patients with uncontrolled hyperthyroidism, certain autoimmune conditions, those receiving organ transplants (due to immune stimulation), or acute active infection.

When can it be initiated alongside conventional treatment?
Often **before or during** systemic therapy once baseline labs and goals are set. Many start **1–2 weeks prior** to chemo/radiation to gauge tolerance; others initiate between cycles. Coordinated with the treating oncologist.

Who prescribes and oversees mistletoe therapy?

In the U.S., mistletoe is typically prescribed by physicians with integrative oncology **training** (MD/DO) and naturopathic doctors where licensed, often in collaboration with the patient's oncology team. Best practice is co-management with clear communication.

Is mistletoe FDA-approved?
Not FDA-approved as a cancer drug. Viscum album appears in the **Homeopathic Pharmacopoeia of the United States**. Use in oncology is **off-label/adjunctive** under clinician supervision.

How is it regulated and obtained in the U.S.?
Products are available through select distributors/clinics under existing regulatory pathways. Importation and clinical use should follow federal and state regulations; institutions may have additional requirements (e.g., P&T review).

Cost and insurance coverage?
Costs vary by brand, route, and dosing frequency. Many patients' self-pay; some can use HSAs/FSAs. Practitioners provide upfront cost estimates and frequency to support informed consent.

How should I counsel a patient already using mistletoe from another provider?
- Clarify goals of care (QOL vs. disease control).
- Reconcile product, dose, schedule, and monitoring plan.
- Check for contraindications, align with current therapy, and agree on shared follow-up

Where can I find reliable information or training?
- Believe Big – Mistletoe Training Resources: https://www.believebig.org
- National Cancer Institute (NCI) PDQ on Mistletoe: https://www.cancer.gov/about-cancer/treatment/cam/hp/mistletoe-pdq
- The Mistletoe Book - https://www.themistletoebook.com/
- Clinical Evidence - https://www.mistletoe-therapy.org/scientific-information/clinical-evidence

Jung ML, Baudino S, Ribéreau-Gayon G, et al.: Characterization of cytotoxic proteins from mistletoe (Viscum album L.). Cancer Lett 51 (2): 103-8, 1990. [PUBMED Abstract]

Kuttan G, Vasudevan DM, Kuttan R: Effect of a preparation from Viscum album on tumor development in vitro and in mice. J Ethnopharmacol 29 (1): 35-41, 1990. [PUBMED Abstract]

Walzel H, Jonas L, Rosin T, et al.: Relationship between internalization kinetics and cytotoxicity of mistletoe lectin I to L1210 leukaemia cells. Folia Biol (Praha) 36 (3-4): 181-8, 1990. [PUBMED Abstract]

Janssen O, Scheffler A, Kabelitz D: In vitro effects of mistletoe extracts and mistletoe lectins. Cytotoxicity towards tumor cells due to the induction of programmed cell death (apoptosis). Arzneimittelforschung 43 (11): 1221-7, 1993. [PUBMED Abstract]

Jurin M, Zarković N, Hrzenjak M, et al.: Antitumorous and immunomodulatory effects of the Viscum album L. preparation Isorel. Oncology 50 (6): 393-8, 1993 Nov-Dec. [PUBMED Abstract]

Schaller G, Urech K, Giannattasio M: Cytotoxicity of different viscotoxins and extracts from the European subspecies Viscum album L. Phytother Res 10 (6): 473-7, 1996.

Gabius HJ, Darro F, Remmelink M, et al.: Evidence for stimulation of tumor proliferation in cell lines and histotypic cultures by clinically relevant low doses of the galactoside-binding mistletoe lectin, a component of proprietary extracts. Cancer Invest 19 (2): 114-26, 2001. [PUBMED Abstract]

Maier G, Fiebig HH: Absence of tumor growth stimulation in a panel of 16 human tumor cell lines by mistletoe extracts in vitro. Anticancer Drugs 13 (4): 373-9, 2002. [PUBMED Abstract]

Franz H: Mistletoe lectins and their A and B chains. Oncology 43 (Suppl 1): 23-34, 1986. [PUBMED Abstract]

Mengs U, Göthel D, Leng-Peschlow E: Mistletoe extracts standardized to mistletoe lectins in oncology: review on current status of preclinical research. Anticancer Res 22 (3): 1399-407, 2002 May-Jun. [PUBMED Abstract]

Podlech O, Harter PN, Mittelbronn M, et al.: Fermented mistletoe extract as a multimodal antitumoral agent in gliomas. Evid Based Complement Alternat Med 2012: 501796, 2012. [PUBMED Abstract]

Schötterl S, Hübner M, Armento A, et al.: Viscumins functionally modulate cell motility-associated gene expression. Int J Oncol 50 (2): 684-696, 2017. [PUBMED Abstract]

Hostanska K, Hajto T, Spagnoli GC, et al.: A plant lectin derived from Viscum album induces cytokine gene expression and protein production in cultures of human peripheral blood mononuclear cells. Nat Immun 14 (5-6): 295-304, 1995. [PUBMED Abstract]

Beuth J, Stoffel B, Ko HL, et al.: Immunomodulating ability of galactoside-specific lectin standardized and depleted mistletoe extract. Arzneimittelforschung 45 (11): 1240-2, 1995. [PUBMED Abstract]

Lenartz D, Stoffel B, Menzel J, et al.: Immunoprotective activity of the galactoside-specific lectin from mistletoe after tumor destructive therapy in glioma patients. Anticancer Res 16 (6B): 3799-802, 1996 Nov-Dec. [PUBMED Abstract]

Fischer S, Scheffler A, Kabelitz D: Oligoclonal in vitro response of CD4 T cells to vesicles of mistletoe extracts in mistletoe-treated cancer patients. Cancer Immunol Immunother 44 (3): 150-6, 1997. [PUBMED Abstract]

Preisfeld A: Influence of aqueous mistletoe preparations on humoral immune parameters with emphasis on the cytotoxicity of human complement in breast cancer patients. Forsch Komplementarmed 4 (4): 224-8, 1997.
Chernyshov VP, Omelchenko LI, Heusser P, et al.: Immunomodulatory actions of Viscum album (Iscador) in children with recurrent respiratory disease as a result of the Chernobyl nuclear accident. Complement Ther Med 5 (3): 141-6, 1997.
Heiny BM, Albrecht V, Beuth J: Correlation of immune cell activities and beta-endorphin release in breast carcinoma patients treated with galactose-specific lectin standardized mistletoe extract. Anticancer Res 18 (1B): 583-6, 1998 Jan-Feb. [PUBMED Abstract]

Stein GM, Schaller G, Pfüller U, et al.: Characterisation of granulocyte stimulation by thionins from European mistletoe and from wheat. Biochim Biophys Acta 1426 (1): 80-90, 1999. [PUBMED Abstract]

Stein GM, Schaller G, Pfüller U, et al.: Thionins from Viscum album L: influence of the viscotoxins on the activation of granulocytes. Anticancer Res 19 (2A): 1037-42, 1999 Mar-Apr. [PUBMED Abstract]

Mistletoe. In: Murray MT: The Healing Power of Herbs. Prima Publishing, 1995, pp 253-9.
Lenartz D, Dott U, Menzel J, et al.: Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe. Anticancer Res 20 (3B): 2073-6, 2000 May-Jun. [PUBMED Abstract]

Steuer-Vogt MK, Bonkowsky V, Ambrosch P, et al.: The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. Eur J Cancer 37 (1): 23-31, 2001. [PUBMED Abstract]

Goebell PJ, Otto T, Suhr J, et al.: Evaluation of an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized phase II trial. J Urol 168 (1): 72-5, 2002. [PUBMED Abstract]

Stauder H, Kreuser ED: Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: current state of clinical research. Onkologie 25 (4): 374-80, 2002. [PUBMED Abstract]

Saha C, Das M, Stephen-Victor E, et al.: Differential Effects of Viscum album Preparations on the Maturation and Activation of Human Dendritic Cells and CD4 T Cell Responses. Molecules 21 (7): , 2016. [PUBMED Abstract]

Hegde P, Maddur MS, Friboulet A, et al.: Viscum album exerts anti-inflammatory effect by selectively inhibiting cytokine-induced expression of cyclooxygenase-2. PLoS One 6 (10): e26312, 2011. [PUBMED Abstract]

Elluru SR, VAN Huyen JP, Delignat S, et al.: Antiangiogenic properties of viscum album extracts are associated with endothelial cytotoxicity. Anticancer Res 29 (8): 2945-50, 2009. [PUBMED Abstract]

Elluru SR, Duong van Huyen JP, Delignat S, et al.: Induction of maturation and activation of human dendritic cells: a mechanism underlying the beneficial effect of Viscum album as complimentary therapy in cancer. BMC Cancer 8: 161, 2008. [PUBMED Abstract]